Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Inflammatory biomarkers and risk of atherosclerotic cardiovascular disease

Inflammatory biomarkers and risk of atherosclerotic cardiovascular disease AbstractBackgroundNon-alcoholic fatty liver disease is an increasing health issue that associates with the development of atherosclerotic cardiovascular disease. This study correlates the association between fatty liver and inflammatory biomarkers with cardiovascular risk scores.MethodologyThis cross-sectional study enrolled 10,181 health examination participants from Northern Taiwan and administered a standardized questionnaire with important biochemical tests and abdominal sonography. To assess concentrations of inflammatory markers high sensitivity C-reactive protein (hs-CRP) and fibrinogen were used.ResultsInflammatory marker levels were significantly increased with increasing fatty liver. In multivariate logistic regression analysis adjusted for major confounding factors, the odds ratios of elevated hs-CRP and fibrinogen were significantly higher in participants with mild or moderate-to-severe fatty liver compared to healthy individuals. The cardiovascular risk scores, above cut-off level 10%, were associated with higher levels of inflammatory biomarkers and fatty liver; odds ratio, 3.52 (2.60-4.77) for non-alcoholic fatty liver disease with hs-CRP, and 2.92 (2.12-4.00) for non-alcoholic fatty liver disease with fibrinogen.ConclusionInflammatory biomarkers (hs-CRP and fibrinogen) are significantly associated with augmentation of fatty liver. Non-alcoholic fatty liver disease may be a predictor of future atherosclerotic cardiovascular disease, and the prediction value increases on adding inflammatory biomarkers levels. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Open Medicine de Gruyter

Inflammatory biomarkers and risk of atherosclerotic cardiovascular disease

Yu, En; Hsu, Hsin-Yin; Huang, Chun-Yuan; Hwang, Lee-Ching
Open Medicine , Volume 13 (1): 6 – May 24, 2018
Download PDF
6 pages

Loading next page...
 
/lp/degruyter/inflammatory-biomarkers-and-risk-of-atherosclerotic-cardiovascular-nbPKzHVqEn

References (26)

Publisher
de Gruyter
Copyright
© 2018 En Yu et al., published by De Gruyter
ISSN
2391-5463
eISSN
2391-5463
DOI
10.1515/med-2018-0032
Publisher site
See Article on Publisher Site

Abstract

AbstractBackgroundNon-alcoholic fatty liver disease is an increasing health issue that associates with the development of atherosclerotic cardiovascular disease. This study correlates the association between fatty liver and inflammatory biomarkers with cardiovascular risk scores.MethodologyThis cross-sectional study enrolled 10,181 health examination participants from Northern Taiwan and administered a standardized questionnaire with important biochemical tests and abdominal sonography. To assess concentrations of inflammatory markers high sensitivity C-reactive protein (hs-CRP) and fibrinogen were used.ResultsInflammatory marker levels were significantly increased with increasing fatty liver. In multivariate logistic regression analysis adjusted for major confounding factors, the odds ratios of elevated hs-CRP and fibrinogen were significantly higher in participants with mild or moderate-to-severe fatty liver compared to healthy individuals. The cardiovascular risk scores, above cut-off level 10%, were associated with higher levels of inflammatory biomarkers and fatty liver; odds ratio, 3.52 (2.60-4.77) for non-alcoholic fatty liver disease with hs-CRP, and 2.92 (2.12-4.00) for non-alcoholic fatty liver disease with fibrinogen.ConclusionInflammatory biomarkers (hs-CRP and fibrinogen) are significantly associated with augmentation of fatty liver. Non-alcoholic fatty liver disease may be a predictor of future atherosclerotic cardiovascular disease, and the prediction value increases on adding inflammatory biomarkers levels.

Journal

Open Medicine – de Gruyter

Published: May 24, 2018

Keywords: Non-alcoholic fatty liver disease; Atherosclerosis; Cardiovascular risk; Inflammatory biomarkers

There are no references for this article.